25 May 2013
Keywords: Targacept, TC-5619, ADHA, Ph II, Study failure, Job cuts
Article | 18 September 2012
In a second disappointment this year, US drug developer Targacept (Nasdaq: TRGT) said yesterday that top-line results from a Phase ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 September 2012
17 September 2012
24 May 2013
© 2013 thepharmaletter.com